Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Non-cash Items (2019 - 2025)

Historic Non-cash Items for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $5.9 million.

  • Fulcrum Therapeutics' Non-cash Items rose 35594.32% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 35594.32%. This contributed to the annual value of $5.4 million for FY2024, which is 6599.13% up from last year.
  • According to the latest figures from Q3 2025, Fulcrum Therapeutics' Non-cash Items is $5.9 million, which was up 35594.32% from $22.2 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Non-cash Items registered a high of $75.6 million during Q3 2021, and its lowest value of $3971.0 during Q2 2022.
  • In the last 5 years, Fulcrum Therapeutics' Non-cash Items had a median value of $3.7 million in 2023 and averaged $10.4 million.
  • As far as peak fluctuations go, Fulcrum Therapeutics' Non-cash Items tumbled by 9968.51% in 2022, and later soared by 7013034.5% in 2023.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' Non-cash Items stood at $1.5 million in 2021, then increased by 27.66% to $1.9 million in 2022, then soared by 701.74% to $15.1 million in 2023, then crashed by 64.58% to $5.4 million in 2024, then grew by 10.41% to $5.9 million in 2025.
  • Its last three reported values are $5.9 million in Q3 2025, $22.2 million for Q2 2025, and $4.6 million during Q1 2025.